Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Dr Chaitman and colleagues1 did not present detailed safety data. In particular,
we would be interested in knowing the effect ranolazine has on kidneys, liver,
blood cells, or metabolism, as well as on quality of life and hospital admission
rates. Furthermore, the authors reported that 30% to 41% of subjects stopped
taking ranolazine, but they did not present their subsequent clinical events.
The fate of these individuals is critical in assessing the safety of this
Pechlaner C, Wiedermann C. Ranolazine as Add-on Therapy for Patients With Severe Chronic Angina. JAMA. 2004;291(16):1959. doi:10.1001/jama.291.16.1959-b